ICU MED INC's ticker is ICUI and the CUSIP is 44930G107. A total of 215 filers reported holding ICU MED INC in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,107,573 | -28.4% | 168,957 | +7.2% | 0.01% | -25.0% |
| Q2 2023 | $28,081,497 | +9.2% | 157,593 | +1.0% | 0.01% | 0.0% |
| Q1 2023 | $25,726,997 | +8.2% | 155,959 | +3.2% | 0.01% | 0.0% |
| Q4 2022 | $23,787,669 | +9.9% | 151,052 | +5.1% | 0.01% | 0.0% |
| Q3 2022 | $21,648,000 | -2.9% | 143,739 | +6.0% | 0.01% | 0.0% |
| Q2 2022 | $22,294,000 | -24.2% | 135,614 | +2.6% | 0.01% | -11.1% |
| Q1 2022 | $29,425,000 | -2.5% | 132,160 | +4.0% | 0.01% | 0.0% |
| Q4 2021 | $30,166,000 | +5.1% | 127,097 | +3.3% | 0.01% | 0.0% |
| Q3 2021 | $28,714,000 | -12.7% | 123,033 | -23.0% | 0.01% | -18.2% |
| Q2 2021 | $32,885,000 | +5.2% | 159,789 | +5.0% | 0.01% | 0.0% |
| Q1 2021 | $31,266,000 | -5.3% | 152,187 | -1.2% | 0.01% | -15.4% |
| Q4 2020 | $33,028,000 | +20.0% | 153,983 | +2.2% | 0.01% | 0.0% |
| Q3 2020 | $27,530,000 | -1.4% | 150,630 | -0.6% | 0.01% | -7.1% |
| Q2 2020 | $27,919,000 | -4.2% | 151,477 | +4.9% | 0.01% | -17.6% |
| Q1 2020 | $29,142,000 | +13.1% | 144,427 | +4.9% | 0.02% | +21.4% |
| Q4 2019 | $25,760,000 | +22.4% | 137,661 | +4.4% | 0.01% | +16.7% |
| Q3 2019 | $21,046,000 | -22.2% | 131,867 | +22.7% | 0.01% | -25.0% |
| Q2 2019 | $27,067,000 | +10.6% | 107,444 | +5.1% | 0.02% | 0.0% |
| Q1 2019 | $24,471,000 | +11.9% | 102,247 | +7.4% | 0.02% | -5.9% |
| Q4 2018 | $21,861,000 | -25.5% | 95,198 | -8.3% | 0.02% | -15.0% |
| Q3 2018 | $29,346,000 | +48.0% | 103,785 | +53.8% | 0.02% | +42.9% |
| Q2 2018 | $19,822,000 | -2.1% | 67,499 | -15.9% | 0.01% | -12.5% |
| Q1 2018 | $20,252,000 | +30.7% | 80,237 | +11.8% | 0.02% | +33.3% |
| Q4 2017 | $15,499,000 | +23.7% | 71,751 | +6.5% | 0.01% | +9.1% |
| Q3 2017 | $12,525,000 | +16.1% | 67,391 | +7.8% | 0.01% | +10.0% |
| Q2 2017 | $10,785,000 | +13.8% | 62,518 | +0.8% | 0.01% | +11.1% |
| Q1 2017 | $9,475,000 | +12.4% | 62,048 | +8.4% | 0.01% | 0.0% |
| Q4 2016 | $8,432,000 | +25.1% | 57,219 | +7.3% | 0.01% | +12.5% |
| Q3 2016 | $6,740,000 | +22.3% | 53,329 | +9.1% | 0.01% | +14.3% |
| Q2 2016 | $5,513,000 | +12.9% | 48,889 | +4.3% | 0.01% | +16.7% |
| Q1 2016 | $4,881,000 | -6.0% | 46,885 | +1.8% | 0.01% | -14.3% |
| Q4 2015 | $5,194,000 | +10.0% | 46,051 | +6.8% | 0.01% | 0.0% |
| Q3 2015 | $4,723,000 | +22.1% | 43,124 | +6.7% | 0.01% | +40.0% |
| Q2 2015 | $3,867,000 | -18.3% | 40,422 | -20.4% | 0.01% | -28.6% |
| Q1 2015 | $4,731,000 | -7.1% | 50,794 | -18.3% | 0.01% | -12.5% |
| Q4 2014 | $5,091,000 | +11.1% | 62,158 | -12.9% | 0.01% | 0.0% |
| Q3 2014 | $4,581,000 | +9.8% | 71,364 | +4.0% | 0.01% | +14.3% |
| Q2 2014 | $4,174,000 | +1.3% | 68,635 | -0.2% | 0.01% | 0.0% |
| Q1 2014 | $4,119,000 | -20.9% | 68,781 | -15.9% | 0.01% | -30.0% |
| Q4 2013 | $5,209,000 | -31.1% | 81,752 | -25.7% | 0.01% | -33.3% |
| Q3 2013 | $7,560,000 | -5.2% | 109,977 | +0.9% | 0.02% | -16.7% |
| Q2 2013 | $7,977,000 | – | 108,974 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EVR Research LP | 22,000 | $4,719,000 | 3.86% |
| NUANCE INVESTMENTS, LLC | 901,483 | $193,359,000 | 3.73% |
| Nitorum Capital, L.P. | 417,241 | $89,494,000 | 3.46% |
| Tamarack Advisers, LP | 73,000 | $15,452,000 | 3.22% |
| PFM Health Sciences, LP | 267,817 | $57,444,000 | 2.02% |
| KIRR MARBACH & CO LLC /IN/ | 22,222 | $4,766,000 | 1.49% |
| PURA VIDA INVESTMENTS, LLC | 174,399 | $37,407,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,584 | $554,000 | 0.88% |
| Findlay Park Partners LLP | 528,825 | $113,428,000 | 0.79% |
| Altium Capital Management LP | 9,321 | $1,999,000 | 0.75% |